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Abstract: OBJECTIVES: Graves’ hyperthyroidism (GH) interferes with iron metabolism and elevates
ferritin. The precise mechanisms remain unclear. The influence of thyroid hormones on the synthe-
sis/regulation of hepcidin, an important regulator of iron metabolism, remains uncharacterized. DE-
SIGN: Prospective observational study. PATIENTS: We included patients (n = 31) with new-onset and
untreated GH. MEASUREMENTS: Laboratory parameters indicative of iron metabolism (ferritin, trans-
ferrin, hepcidin), inflammatory markers/cytokines and smoking status were assessed at the diagnosis of
GH (T0) and at euthyroidism (T1) in the same patients using multivariable analyses. Hepcidin was
measured by mass spectrometry (hepcidinMS ) and ELISA (hepcidinEL ). The impact of T3 on hepatic
hepcidin expression was studied in a cell culture model using HepG2 cells. RESULTS: Median ferritin
levels were significantly lower and transferrin significantly higher at T1 than at T0. HepcidinMS levels
were lower in males and females at T1 (statistically significant in males only). No statistically significant
difference in hepcidinEL was detected between T0 and T1. Plasma levels of inflammatory markers (high-
sensitive CRP, procalcitonin) and cytokines (interleukin 6, interleukin 1ß, tumour necrosis factor ￿) were
not different between T0 and T1. Smokers tended to have lower fT3 and fT4 at T0 than nonsmoking
GH patients. T3 significantly induced hepcidin mRNA expression in HepG2 cells. CONCLUSIONS:
Iron metabolism in patients with GH undergoes dynamic changes in patients with GH that resemble an
acute-phase reaction. Inflammatory parameters and cytokines were unaffected by thyroid status. Gender
and smoking status had an impact on ferritin, hepcidin and thyroid hormones.
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Objectives:	Graves’	 hyperthyroidism	 (GH)	 interferes	with	 iron	metabolism	 and	 ele-
vates	 ferritin.	 The	 precise	 mechanisms	 remain	 unclear.	 The	 influence	 of	 thyroid	







variable	 analyses.	 Hepcidin	 was	 measured	 by	 mass	 spectrometry	 (hepcidinMS)	 and	
ELISA	(hepcidinEL).	The	impact	of	T3	on	hepatic	hepcidin	expression	was	studied	in	a	
cell	culture	model	using	HepG2	cells.
Results:	Median	 ferritin	 levels	were	 significantly	 lower	 and	 transferrin	 significantly	
higher	 at	T1	 than	 at	T0.	HepcidinMS	 levels	were	 lower	 in	males	 and	 females	 at	T1	
	(statistically	significant	in	males	only).	No	statistically	significant	difference	in	hepcidi-
nEL	was	detected	between	T0	and	T1.	Plasma	levels	of	inflammatory	markers	(high-	
sensitive	 CRP,	 procalcitonin)	 and	 cytokines	 (interleukin	 6,	 interleukin	 1ß,	 tumour	





cytokines	 were	 unaffected	 by	 thyroid	 status.	 Gender	 and	 smoking	 status	 had	 an	
	impact	on	ferritin,	hepcidin	and	thyroid	hormones.
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1  | INTRODUCTION
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In	 severe	 hyperthyroidism	 normochromic,	 normocytic	 anaemia	
may	be	associated	with	impaired	iron	use.1,2	These	anaemias	are	un-
responsive	to	haematinic	 therapy2	 (ie	substitution	with	 iron,	vitamin	












iron	 efflux	 out	 of	 cells	 (enterocytes,	 hepatocytes	 or	macrophages).4,5 
The	bioactive	form	of	hepcidin	(hepcidin-	25)	contains	25	amino	acids.	





















others	 did	 not.14	 Furthermore,	 the	mechanisms	 of	 hyperthyroidism-	
associated	hyperferritinaemia	remain	poorly	understood.
Here,	 we	 hypothesize	 that	 thyroid	 hormones	 directly	 influence	
iron	metabolism	by	affecting	ferritin	and/or	hepcidin	levels.	Therefore,	
the	aims	of	this	study	were	as	follows:
•	 To	 quantify	 the	 levels	 of	 ferritin,	 hepcidin	 and	 other	 parameters	
related	to	iron	metabolism	(eg	transferrin)	in	patients	with	Graves’	
hyperthyroidism	 (GH)	 and	 in	 the	 same	 patients	 after	 they	 had	
achieved	euthyroidism.
•	 To	 investigate	 potential	 mechanisms	 by	 measuring	 inflammatory	
parameters	and	cytokines	and	to	set	these	measurements	in	rela-
tion	to	gender	and	smoking	status.
•	 To	 study	 the	 impact	 of	 thyroid	 hormones	 on	 hepatic	 hepcidin	
	expression	using	a	cell	culture	model.
2  | SUBJECTS AND METHODS
This	was	a	prospective	observational	study.	The	subjects	consisted	of	
patients	who	attended	our	outpatient	clinic	with	newly	diagnosed	and	
untreated	Graves’	 hyperthyroidism	 (GH).	 Exclusion	 criteria	were	 the	
following:	age	below	18	years,	pregnancy/planned	pregnancy,	known	
hepatopathy,	 alcohol	 abuse	 (defined	as	 consumption	of	≥3	 standard	
drinks	 per	 day	 in	 females	 or	 ≥4	 standard	 drinks	 per	 day	 in	 males),	
known/treated	iron	deficiency,	active	malignancy,	chronic	renal	insuf-
ficiency	 (≥	 chronic	kidney	disease	 stage	 III)	 and	acute/chronic	 infec-
tions.	Laboratory	parameters	were	assessed	in	patients	at	the	diagnosis	
of	GH	 (T0)	and	after	 they	 reached	euthyroid	 function	 (T1)	 following	
treatment	with	 antithyroid	 therapy	 (carbimazole	 or	 propylthiouracil).	
Euthyroid	 function	was	 defined	 as	 the	 presence	 of	 normal	 thyroid-	
stimulating	hormone	(TSH)/free	triiodothyronine	(fT3)	and	free	thyrox-
ine	 (fT4)	values	 for	at	 least	4	weeks.	Thyroid	volume	was	calculated	
using	B-	mode	standard	ultrasonography.	All	patients	gave	their	written	
informed	consent.	The	study	conformed	to	the	declaration	of	Helsinki	
and	was	 approved	 by	 the	 local	 ethics	 committee	 (approval	 number:	
EKNZ-	13077).
2.1 | Laboratory assessment
Indicators	of	 thyroid	 function	 (TSH,	 fT3,	 fT4,	anti-	TSH-	receptor	an-
tibodies),	 iron	 metabolism	 (ferritin,	 transferrin,	 iron,	 soluble	 trans-
ferrin	 receptor	 [sTfR])	 and	 inflammation	 (high-	sensitive	 c-	reactive	
protein	 [hsCRP],	 procalcitonin)	 were	 measured	 using	 electrochemi-
luminescence	immunoassays	(ECLIA,	Roche	COBAS®	System,	Roche	




mass	 spectrometry	 for	 the	 determination	 of	 bioactive	 hepcidin-	25	




MD,	USA),	which	 detects	 hepcidin-	25	 and	 other	 hepcidin	 	isoforms.	
Measurement	 of	 cytokines	 was	 performed	 using	 a	 flowcytometric	
method.
2.2 | Cell culture
HepG2	 cells	 were	 cultured	 in	 Dulbecco’s	 modified	 Eagle’s	 medium	







(NucleoSpin®,	 Macherey-	Nagel,	 Düren,	 Germany)	 and	 reverse-	
transcribed	(Takara	Bio	Europe,	Saint-	Germain-	en-	Laye,	France),	and	
quantitative	 real-	time	PCR	was	performed	 as	described.18	Hepcidin	




The	 values	 for	 each	 parameter	were	 compared	 at	 baseline	 (T0)	 and	
follow-	up	 (T1),	 as	 defined	 above.	 Initially,	 data	 were	 analysed	 de-
scriptively	by	calculating	medians	and	interquartile	ranges	(IQRs).	The	
statistical	 significance	 of	 any	 differences	 was	 established	 using	 the	
nonparametric	Wilcoxon	matched-	pairs	signed-	rank	test.	For	the	main	







Parameter (unit) Reference range
n Complete measurement 
pairs (T0&T1) Baseline (T0) Follow- up (T1) P- valuea













































































































The	main	 exposure	 of	 interest	 in	 our	multivariable	 analysis	was	
the	time	point	(baseline	T0	or	follow-	up	T1).	The	following	variables	
were	considered	 for	model	adjustment:	 age,	gender,	 smoking	status	
and	time	between	baseline	and	follow-	up	(in	days).	We	also	tested	for	
interactions	with	gender	and	smoking	status.	These	interaction	tests	













mL,	 and	 thyroid	 parameters	 are	 displayed	 in	 Table	1.	 Patients	 were	
treated	 either	 with	 carbimazole	 (n	=	29)	 or	 propylthio	uracil	 (n	=	2).	
Two	patients	had	normochromic,	normocytic	anaemia	at	baseline	that	
resolved	 at	 T1,	 but	 none	had	 laboratory	 values	 consistent	with	 iron	
deficiency	(ie	ferritin	index	≥3	or	soluble	transferrin	receptor	>5	mg/L).
Restoring	 normal	 thyroid	 function	 led	 to	 a	 rise	 of	 transferrin 
and plasma iron	 (values	 for	 iron	at	T1	not	 significant).	By	contrast,	
transferrin	 saturation	 and	 soluble	 transferrin	 receptor	 levels	were	
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decreased	 significantly	 after	 euthyroid	 function	 had	 been	 achieved	
(Table	1,	Figure	1).
Median	 (IQR)	 hepcidinMS	 concentrations	 at	 baseline	 were	 9.15	
(6.45-	17.25)	 nmol	L−1	 and	 were	 higher	 in	 males	 (17.1	 [10.5-	26.9]	
nmol	L−1)	 than	 in	 females	 (8.3	 [6.3-	13.6]	 nmol	L−1).	As	with	 ferritin,	
















sexes	 for	 ferritin	 (estimated	 difference	 between	males	 and	 females	
TABLE  2 Multivariable	regression	analyses
Ferritin (μg/L) HepcidinMS (nmol L−1)
Univariable Multivariable Univariable Multivariable




Female	sex −259.29 (−450.93; −67.65) −9.07 (−16.57; −1.58)
Smoker
Time	between	T0	and	T1 −1.50 (−3.16; 0.16)
Change	from	T0	to	T1 −107.39 (−155.83; −58.94) −217.67 (−344.81; −90.52) −4.86 (−7.40; −2.33) −8.35 (−12.99; −3.71)
Interaction	of	T1	and	
female	sexa
155.39 (24.97; 285.82) 6.57 (1.21; 11.92)
Interaction	of	T1	and	
smokingb
fT3 (pmol L−1) fT4 (pmol L−1)
Univariable Multivariable Univariable Multivariable




Smoker −6.14 (−11.11; −1.16) −18.18 (−31.15; −5.21)
Time	between	T0	and	T1
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[95%	confidence	interval	(CI)]:	103.9	μg/L	[22.9;	184.9]),	but	not	for	
hepcidin	(2.5	nmol	L−1	[−0.9;	6.0]).
Further,	 the	 regression	models	 for	 fT4	 and	 fT3	 indicated	differ-
ences	 in	 the	 dynamics	 of	 changes	 between	 smokers	 and	 nonsmok-
ers	(Figure	3a/b).	In	particular,	smokers	had	lower	fT3	and	fT4	at	T0	
(model	estimates	[95%	CI]	for	differences	between	nonsmokers	and	
smokers	 of	 −6.1	pmol	L−1	 [−11.1;	 −1.2]	 and	 −18.2	 pmol	L−1	 [−31.1;	
−5.2],	 respectively).	 During	 follow-	up,	 these	 laboratory	 parameters	























ride	 and	 nitric	 oxide)	 regulate	 ferritin	 by	 inducing	 the	 transcription,	
stimulating	 the	 secretion	 and	 modulating	 the	 post-	transcriptional	






flammatory	 reaction,	but	markers	of	 inflammation	and	 inflammatory	
cytokines	 in	our	patients	were	not	affected	neither	by	thyroid	func-


































tages	 of	 including	 only	 patients	with	GH,	 using	 longitudinal	 assess-
ments	of	laboratory	values	and	measuring	a	novel	variable	related	to	
iron	metabolism	(hepcidin).	Our	study	design	allowed	us	to	compare	
and	 demonstrate	 the	 dynamic	 changes	 in	 ferritin	 and	 hepcidin	 that	
occur	in	the	same	individuals	during	thyroid	hyperfunction	and	after	










ings	 showing	no	 statistically	 significant	differences	 in	hepcidin	 levels	
between	time	points	when	hepcidin	levels	were	measured	using	ELISA.
The	 study	 has	 two	 principal	 limitations:	 the	 sample	 size	 was	
small	and	only	 fraction	of	 the	 factors	 (eg	cytokines)	 that	are	known	




and	 the	 underlying	 mechanisms	 is	 critical,	 allowing	 the	 clinician	
to	 estimate	 the	 impact	 of	 thyroid	 function	 abnormalities	 on	 these	
	parameters,	 to	 consider	 other	 differential	 diagnoses	 and	 to	 prevent	












thyroid	status.	For	 the	 first	 time,	we	were	able	 to	demonstrate	 that	
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